Supporting Treatment Adherence Readiness Through Training (START)

RAND240 enrolled

Overview

Multi-site, randomized controlled trial of the Adherence Readiness Program (ARP) adherence intervention for HIV clients starting or restarting antiretroviral therapy (ART) for the purpose of achieving and sustaining optimal levels of ART adherence and virologic suppression. Eligible participants will be randomized to receive either the ARP intervention or usual care (no intervention) and followed for 24 months.

This study will evaluate the effects of the Adherence Readiness Program (ARP) intervention on the primary outcomes of dose-taking HIV antiretroviral (ART) adherence and undetectable HIV viral load in a multi-site randomized controlled trial. The ARP is based on the Information Motivation Behavioral skills (IMB) model of behavior change and includes (1) brief pill taking practice trials for enhancing pre-treatment adherence counseling and providing a behavioral criterion for determining adherence readiness and the start of treatment, and (2) a performance driven dose regulation mechanism to tailor the amount of counseling (from pre-treatment through the full course of treatment) to the individual needs of the patient and conserve limited resources. Participants will be randomized to receive either the ARP (adherence counseling sessions) or usual care. Primary assessments will be administered at screening and every 6 months after ART initiation over a 24-month follow-up, making it one of the few studies to examine intervention effects longer than one year. Secondary outcomes include dose-timing adherence and CD4 count. If effective, the ARP will provide clinicians with an intervention that (1) informs providers and patients when the patient is ready to adhere well and start treatment, (2) enhances adherence readiness from the outset of treatment through the full course of therapy, and (3) tailors the amount of adherence support based on individual patient need and performance, thus more efficiently using clinic resources, fostering better acceptance from providers and patients, and increasing the likelihood of successful program adoption and dissemination. This emphasis on efficient use of resources will be complemented by a cost-effectiveness analysis to further inform policy decisions regarding the transportability of the intervention and its potential for more wide scale use and sustainability if effective.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

240

Conditions

HIV Medication Adherence

Interventions

Adherence Readiness ProgramBEHAVIORAL

The ARP consists of pre-treatment (including practice trials to determine readiness for and timing of ART initiation), early-treatment, and ongoing maintenance training (using a performance-based, dose regulation mechanism to tailor the amount and intensity) phases

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. The patient's provider views the patient as medically appropriate to begin (ART naïve) or restart ART (has been off ART for at least 2 months), and either * plans to start the patient on ART * would like to start the patient on ART but the provider or patient is uncertain about the patient's readiness to adhere well. Patients who are currently on ART are also eligible if they meet the following criteria, which are specific only to this type of patient: i) the patient has 2 or more HIV viral load tests in the past year \> 1000 copies/ml ii) the patient has had no HIV viral load tests that were undetectable in the past year iii) the patient has a genotype in the past year that does not show resistance as a reason for virologic failure (detectable viral load) iv) primary care provider views the patient as a good candidate for the study, with the understanding that the patient will interrupt ART if assigned to the intervention. Criteria i to iii are intended to define a subgroup of nonadherent patients who are taking very little of their ART medications, as evidenced by the combination of consistently high viral load and no drug resistance. If the patient was taking at least a moderate level of drug and still had consistently high viral load, than they would have evidence of drug resistance. Providers are generally comfortable with this type of patient stopping their medication in order to facilitate the pre-treatment, adherence readiness assessment and training phase of the intervention prior to restarting the patient on treatment. 2. The patient's health status is stable. There is no current acute OI or medical condition that calls for immediate ART, as determined by the patient's provider. 3. Most recent HIV viral load is detectable. 4. If CD4 \< 200, the patient is on or will be prescribed prophylactic medication 5. Patient is 18 or older. 6. Patient is able and willing to give informed consent. 7. English speaking. Exclusion Criteria: 1\. Patient just tested HIV+ and their provider suspects the patient may be acutely or recently infected (within past 6 months).

Locations (3)

CARE CLinic

Long Beach, California, United States

T.H.E. Clinic

Los Angeles, California, United States

UCLA Care Center

Los Angeles, California, United States

Outcomes

Primary Outcomes

HIV virologic suppression

undetectable HIV viral load at time of assessment

Time frame: Month 24

log change in HIV viral load (log change in HIV RNA levels)

log change in HIV RNA levels from baseline to Month 24.

Time frame: Month 24

optimal dose-taking adherence (whether at least 85% of prescribed doses were taken)

binary variable representing whether at least 85% of prescribed doses were taken between baseline and Month 24

Time frame: Month 24

percent dose-taking adherence

percent of prescribed doses taken between baseline and Month 24

Time frame: Month 24

HIV virologic suppression

undetectable HIV viral load at time of assessment

Time frame: Month 6

log change in HIV viral load (log change in HIV RNA levels)

log change in HIV RNA levels from baseline to Month 6

Time frame: Month 6

optimal dose-taking adherence (whether at least 85% of prescribed doses were taken)

binary variable representing whether at least 85% of prescribed doses were taken between baseline and Month 6

Time frame: month 6

percent dose-taking adherence

percent of prescribed doses taken between baseline and Month 6

Time frame: month 6

Secondary Outcomes

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

dose-timing adherence

percent of prescribed doses taken within correct time-window between baseline and Month 24

Time frame: Month 24

dose-timing adherence

percent of prescribed doses taken within correct time-window between baseline and Month 6

Time frame: Month 6

optimal dose-timing adherence

binary variable representing whether at least 85% of prescribed doses were taken within correct time-window between baseline and Month 24

Time frame: Month 24

optimal dose-timing adherence

binary variable representing whether at least 85% of prescribed doses were taken within correct time-window between baseline and Month 6

Time frame: Month 6

change in CD4 count

change in CD4 count from baseline to Month 24

Time frame: Month 24

change in CD4 count

change in CD4 count from baseline to Month 6

Time frame: Month 6

clinic attendance (number of missed clinic appointments)

number of missed clinic appointments between baseline and Month 24

Time frame: Month 24

clinic attendance (number of missed clinic appointments)

number of missed clinic appointments between baseline and Month 6

Time frame: Month 6